RAPT Therapeutics
RAPT
RAPT was delisted on the 2nd of March, 2026.
50 hedge funds and large institutions have $136M invested in RAPT Therapeutics in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 34 reducing their positions, and 45 closing their positions.
152% more call options, than puts
Call options by funds: $295K | Put options by funds: $117K
0.4% more ownership
Funds ownership: 12.42% → 12.82% (+0.4%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
15% less capital invested
Capital invested by funds: $160M → $136M (-$24.4M)
46% less funds holding
Funds holding: 92 → 50 (-42)
74% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 34
91% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 45
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Column Group
San Francisco,
California
|
+$8.87M |
| 2 |
FIS
FCPM III Services
Naarden,
Netherlands
|
+$3.36M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.48M |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$281K |
| 5 |
SCM
Superstring Capital Management
New York
|
+$199K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$2.81M |
| 2 |
BlackRock
New York
|
-$1.58M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$1.36M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.18M |
| 5 |
State Street
Boston,
Massachusetts
|
-$556K |
RAPT Hedge Fund Activity: Q2 2025 in Review
50 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q2 2025, worth a combined $136M — down 15% from $160M a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of RAPT and 4 opened new positions — a net loss of 41 holders — while 34 trimmed existing stakes and 9 added.
The largest buyer was Column Group, adding an estimated $8.87M. The largest seller was Perceptive Advisors, cutting an estimated $2.81M.
- 50 institutional investors held RAPT Therapeutics (RAPT) as of Q2 2025, down from 92 in Q1 2025.
- Funds reported $136M of RAPT Therapeutics stock for Q2 2025, down 15% quarter-over-quarter.
- 4 funds opened new RAPT Therapeutics positions in Q2 2025 and 45 closed out, a net change of -41 holders.
- The largest RAPT Therapeutics buyer in Q2 2025 was Column Group, an estimated $8.87M added.
- The largest RAPT Therapeutics seller in Q2 2025 was Perceptive Advisors, an estimated $2.81M sold.
Based on aggregated 13F filings for Q2 2025.